NURE-COMBO: Patient Population, Regimen, and Efficacy in MIBC

Real-world data support the effectiveness of combining platinum-based chemotherapy with PD-1 inhibitors for recurrent limited-disease small cell lung cancer (SCLC), enhancing patient outcomes.

Sadie Dobrozsi, MD, of Evolent, discusses how predictive genomics is pushing cancer care into a new era of personalization

The CRL was given because the FDA did not consider the phase 1/2 IGNYTE trial to be an adequate and well-controlled clinical investigation to provide substantial evidence to support approval

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

Flatiron Health expands its international oncology research network, enhancing real-world data use to improve patient outcomes and cancer care globally.

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly impact outcomes for patients with traditionally poor prognoses and limited options.